Pulsenmore Ltd. (TLV:PULS)
Israel
· Delayed Price · Currency is ILS · Price in ILA 259.60
-4.00 (-1.52%)
At close: Dec 4, 2025
Pulsenmore Revenue
Pulsenmore had revenue of 4.00M ILS in the half year ending June 30, 2025, with 64.57% growth. This brings the company's revenue in the last twelve months to 9.31M, up 14.82% year-over-year. In the year 2024, Pulsenmore had annual revenue of 9.66M with 56.12% growth.
Revenue (ttm)
9.31M
Revenue Growth
+14.82%
P/S Ratio
14.47
Revenue / Employee
160.52K
Employees
58
Market Cap
134.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.66M | 3.47M | 56.12% |
| Dec 31, 2023 | 6.19M | -4.63M | -42.78% |
| Dec 31, 2022 | 10.81M | 9.24M | 585.30% |
| Dec 31, 2021 | 1.58M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Kamada | 578.74M |
| BrainsWay | 162.56M |
| Bait Bakfar | 107.78M |
| SofWave Medical | 255.13M |
| Ilex Medical | 915.05M |
| Novolog (Pharm-Up 1966) | 1.97B |